Klaria Interim Report Q1 2023

Summary of the Interim Report

Net sales of 6.5 MSEK (0.0 MSEK)

Other income amounted to 0.1 MSEK (0.1 MSEK)

First quarter of 2023

- R&D costs for the period amounted to 8.6 MSEK (17.2 MSEK)

- Profit after tax amounted to -5.4 MSEK (-20.3 MSEK)

- Earnings per share for the quarter amounted to -0.06 SEK (-0.37 SEK)

- Cash flow from operating activities amounted to -9.1 MSEK (-19.8 MSEK)

- Cash and cash equivalents on the balance sheet date amounted to 13.1 MSEK (23.0 MSEK)

- Cash and cash equivalents on the balance sheet date amounted to 70.7 MSEK (72.1 MSEK)

- Klaria receives payment of 2.6 MSEK from Imbrium Therapeutics within the R&D collaboration for Adrenaline Alginate Film

For more information, visit the  Klaria Pharma Holding website klaria.com or contact:
Jesper Wiklund, CEO Klaria Pharma Holding AB (publ)
investor.relations@klaria.com
Tel: +46 (0) 8-446 42 99

This is Klaria Pharma Holding AB

Klaria (Klaria Pharma Holding AB) is a Swedish listed pharmaceutical company that develops innovative, rapid-acting products. By combining patented technology of a film that attaches to the oral mucosa and well proven pharmaceuticals, the company has developed a drug distribution concept with many benefits and potential uses. Klaria is listed on Nasdaq First North Growth Markets under the short name KLAR. FNCA Sweden is Certified Advisor (info@fnca.se, +46(0) 8-528 00 399) for Klaria Pharma Holding AB. For more information, see www.klaria.com.